Document is current
Any future updates will be listed below
-
Authors
Mallardo, Domenico https://orcid.org/0000-0002-1081-5313
Fordellone, Mario https://orcid.org/0000-0003-0790-892X
White, Andrew
Ottaviano, Margaret https://orcid.org/0000-0001-9589-0808
Sparano, Francesca https://orcid.org/0000-0003-3348-6281
Bailey, Michael https://orcid.org/0000-0002-2727-4883
Facchini, Arianna Bianca https://orcid.org/0000-0001-7564-5100
Ong, Sufey
Maiolino, Piera https://orcid.org/0000-0002-8473-2254
Caracò, Corrado https://orcid.org/0000-0002-7828-079X
Church, Sarah
Cavalcanti, Ernesta https://orcid.org/0000-0001-6302-1579
Warren, Sarah
Budillon, Alfredo https://orcid.org/0000-0002-6330-6053
Cesano, Alessandra
Simeone, Ester https://orcid.org/0000-0003-2964-0434
Chiodini, Paolo https://orcid.org/0000-0003-0139-2264
Ascierto, Paolo Antonio https://orcid.org/0000-0002-8322-475X
- License Information
-
More Information
Article History
Received: 12 July 2023
Accepted: 5 August 2023
First Online: 8 September 2023
Declarations
:
: All subjects provided informed written consent prior to enrollment in the study. All procedures performed were in accordance with the 1964 Helsinki declaration and its later amendments. This study was approved by the Ethics Committee of Istituto Nazionale Tumori—IRCCS—Fondazione “G. Pascale”, Naples, Italy, protocol number 17/17 oss. All patients released informed consent to participate.
: All participants released consent to the publication of anonymous data.
: PAA has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi. AC received grant consultancies from BMS, Astrazeneca, Roche and MSD. He also received speaker’s fee from Astrazeneca, Novartis and Eisai.
